Investigating the Efficacy of Ergothioneine to Delay Cognitive Decline (Pilot)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Mild Cognitive Impairment
Interventions
DRUG

L-ergothioneine

Ergothioneine is naturally occurring thiol compound obtained solely from diet in humans. Ergothioneine is widely reported to be a natural antioxidant and anti-inflammatory compound. In addition we hypothesize that this compound will be beneficial in improving cognition.

DRUG

Placebo

Placebo. Study control (99% microcrystalline cellulose, 1% magnesium stearate)

Trial Locations (1)

119074

National University Cancer Institute, Singapore, Singapore

All Listed Sponsors
collaborator

National University of Singapore

OTHER

collaborator

National University Health System, Singapore

OTHER

lead

National University Hospital, Singapore

OTHER

NCT03641404 - Investigating the Efficacy of Ergothioneine to Delay Cognitive Decline (Pilot) | Biotech Hunter | Biotech Hunter